Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.

Abstract

UNLABELLED:

Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear. A total of 111 HIV-HBV-infected patients undergoing TDF-containing antiretroviral therapy were prospectively followed. Serum HBV-DNA viral load, hepatitis surface (HBsAg) and e antigen (HBeAg) status were obtained at baseline and every 6-12 months. Amino acid (aa) changes on the polymerase gene were assessed using direct sequencing after nested polymerase chain reaction in patients with persistent viremia (PV). After a median of 74.7 months (interquartile range: 33.4-94.7), virological response (VR; <60 IU/mL) occurred in 96 of 111 (86.5%) patients. Of these, 86 of 96 (89.6%) remained completely undetectable during follow-up (stabilized VR). The remaining 10 of 96 (10.4%) patients had a transient blip of detectable HBV-DNA (transient PV), during which time 9 of 9 (100%) with available samples had detectable plasma TDF. Low-level PV (LL-PV; 61-2,000 IU/mL) was observed in 11 of 111 (9.9%) patients, the majority of which had detectable plasma TDF (8 of 9; 88.9%). High-level PV (>2,000 IU/mL) was rare (4 of 111; 3.6%) and was associated with nonadherence. At TDF initiation, patients with stabilized VR had significantly higher nadir CD4(+) count, compared to those with transient PV (P = 0.006) or LL-PV (P = 0.04). No consistent aa changes, other than those associated with lamivudine resistance, were observed in patients with persistent viremia. Importantly, HBeAg loss, HBeAg seroconversion, and HBsAg loss only occurred in patients with stabilized VR. Two patients with stabilized VR developed hepatocellular carcinoma and 2 with LL PV died, 1 of a liver-related cause.

CONCLUSION:

Suboptimal HBV control during TDF treatment has a negative effect on serological outcomes, but not necessarily clinical events. Immunoregulation may provide more insight into this phenomenon.

• Authors: Anders Boyd, Joël Gozlan, Sarah Maylin, Constance Delaugerre, Gilles Peytavin, Pierre-Marie Girard, Fabien Zoulim, Karine Lacombe
• Journal: Hepatology (Baltimore, Md.) (Hepatology) Vol. 60 Issue 2 Pg. 497-507 (Aug 2014) ISSN: 1527-3350 [Electronic] United States
• PMID: 24752996 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
• Copyright: © 2014 by the American Association for the Study of Liver Diseases.

Chemical References

• DNA, Viral
• Hepatitis B e Antigens
• Organophosphonates
• Reverse Transcriptase Inhibitors
• Tenofovir
• Adenine

Topics

• Adenine (administration & dosage, analogs & derivatives)
• Adult
• Coinfection (blood, drug therapy)
• DNA, Viral (blood, genetics)
• Drug Resistance, Viral
• Female
• Follow-Up Studies
• Genotype
• HIV Infections (blood, drug therapy)
• Hepatitis B e Antigens (blood)
• Hepatitis B virus (drug effects, genetics)
• Hepatitis B, Chronic (blood, drug therapy)
• Humans
• Male
• Middle Aged
• Organophosphonates (administration & dosage)
• Prospective Studies
• Reverse Transcriptase Inhibitors (administration & dosage)
• Tenofovir
• Treatment Outcome
• Viral Load (drug effects)
• Viremia (blood, drug therapy)
• Virus Replication (drug effects)